You are here

HIV Drug Doravirine Succeeds in Phase 3 Trial

Data show noninferiority to darunavir

Positive results have been announced from a pivotal phase 3 trial evaluating the safety and efficacy of doravirine (Merck), an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI). The study met its primary efficacy endpoint of the proportion of participants achieving levels of human immunodeficiency virus-1 (HIV-1) RNA of less than 50 copies/mL after 48 weeks of treatment, demonstrating the noninferiority of once-daily doravirine compared with once-daily ritonavir-boosted darunavir (DRV+r), each administered with tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) or abacavir/lamivudine (ABC/3TC), in treatment-naïve adults with HIV-1 infection.

In addition, a secondary endpoint showed that the doravirine-treated group had significantly lower levels of fasting low-density lipoprotein cholesterol (LDL-C) compared with the DRV+r group.

The DRIVE-FORWARD trial was a multicenter, double-blind, randomized, noninferiority study in which 769 treatment-naïve adults with HIV-1 infection received either doravirine 100 mg or darunavir 800 mg plus ritonavir 100 mg, both administered orally once-daily in combination with either TDF/FTC or ABC/3TC. After 48 weeks of treatment, the proportions of subjects achieving levels of HIV-1 RNA of less than 50 copies/mL after once-daily doravirine or once-daily DRV+r, each in combination with either TDF/FTC or ABC/3TC, were 84% (321/383) and 80% (306/383), respectively. Increases in mean CD4+ T-cell counts from baseline were similar for the doravirine and DRV+r treatment groups: 193 and 186 cells/mm3, respectively.

In addition, comparable efficacy was observed in subjects with baseline levels of HIV-1 RNA of greater than 100,000 copies/mL: 81% (64/79) for doravirine and 76% (55/72) for DRV+r. One out of 383 subjects developed phenotypic and genotypic resistance in the doravirine arm; this patient was omitted from the study at week 24 because of nonadherence. None of the 383 participants receiving DRV+r developed phenotypic or genotypic resistance.

The rates of reported adverse events were 31% (117/383) for doravirine and 32% (123/383) for DRV+r. Discontinuations due to adverse events for the doravirine and DRV+r groups were 2% (6/383) and 3% (12/383), respectively. The most common adverse events associated with doravirine and DRV+r included diarrhea (14% vs. 22%, respectively), headache (14% vs. 11%), nausea (11% vs. 12%), and nasopharyngitis (8% vs. 10 %).

An analysis of fasting serum blood lipids for the doravirine and DRV+r groups showed a statistically significant difference (P < 0.0001) in mean changes from baseline in the levels of LDL-C (–4.5 mg/dL vs. +9.9 mg/dL, respectively) and in levels of non–high-density lipoprotein cholesterol (non–HDL-C) (–5.3 mg/dL vs. +13.8 mg/dL). Mean changes from baseline in total cholesterol, HDL-C, and triglycerides were –1.4 mg/dL, +3.9 mg/dL, and –3.1 mg/dL for the doravirine group compared with +17.9 mg/dL, +4.2 mg/dL, and +22 mg/dL for the DRV+r group.

Source: Merck; February 15, 2017.

More Headlines

Health care squabbles continue as government shutdown looms
Some drug makers may “game” approval system
Secret shell company acquired lab equipment, lawsuit charges
PCSK9 inhibitor lowers low-density lipoprotein-cholesterol levels
Trump offers to support Obamacare subsidies if Dems okay cash for his border wall
For each physician, eight workers fill jobs unrelated to patient care
Drug giants eye potential $35 billion market
Renflexis gets the nod for all Remicade indications